Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA GENE THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER FIVE ANALYSIS
5 UPDATE ON GERMLINE GENE THERAPY
5.1 GERMLINE GENE THERAPY
6 NORTH AMERICA GENE THERAPY MARKET, MO
6.1 DRIVERS
6.1.1 NOVEL APPROACHES TO GENE THERAPY
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE
6.2 RESTRAINTS
6.2.1 HIGH COST OF GENE THERAPY
6.2.2 ETHICAL AND SAFETY CONCERNS
6.2.3 COMPLEXITY OF GENE THERAPY
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS
6.4.2 LONG-TERM SAFETY AND EFFICACY
7 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE
7.1 OVERVIEW
7.2 VIRAL VECTOR
7.2.1 ADENOVIRUS
7.2.2 RETROVIRUS
7.2.3 LENTIVIRUS
7.2.4 ADENO-ASSOCIATED VIRUS
7.2.5 VACCINIA VIRUS
7.2.6 HERPES SIMPLEX VIRUS
7.2.7 OTHERS
7.3 NON-VIRAL VECTOR
7.3.1 LIPOFECTION
7.3.2 INJECTION OF NAKED DNA
8 NORTH AMERICA GENE THERAPY MARKET, BY METHOD
8.1 OVERVIEW
8.2 EX-VIVO
8.3 IN-VIVO
9 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGICAL DISORDERS
9.3 CARDIOVASCULAR DISEASES
9.4 INFECTIOUS DISEASES
9.5 RARE DISEASES
9.6 NUEROLOGICAL DISORDERS
9.7 OTHER DISEASES
10 NORTH AMERICA GENE THERAPY MARKET, BY END USER
10.1 OVERVIEW
10.2 CANCER INSTITUTES
10.3 HOSPITALS
10.4 RESEARCH INSTITUTES
10.5 OTHERS
11 NORTH AMERICA GENE THERAPY MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA GENE THERAPY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 COMPANY PROFILES
13.1 BIOGEN
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 SWOT ANALYSIS
13.1.5 PRODUCT PORTFOLIO
13.1.6 RECENT DEVELOPMENT
13.2 KITE PHARMA
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 SWOT ANALYSIS
13.2.5 PRODUCT PORTFOLIO
13.2.6 RECENT DEVELOPMENT
13.3 NOVARTIS AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 SWOT ANALYSIS
13.3.5 PRODUCT PORTFOLIO
13.3.6 RECENT DEVELOPMENTS
13.4 BRISTOL-MYERS SQUIBB COMPANY.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 SWOT ANALYSIS
13.4.5 PRODUCT PORTFOLIO
13.4.6 RECENT DEVELOPMENT
13.5 OXFORD BIOMEDICA
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 SWOT ANALYSIS
13.5.5 PRODUCT PORTFOLIO
13.5.6 RECENT DEVELOPMENTS
13.6 AGC BIOLOGICS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ANGES, INC
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.9 BLUEBIRD BIO, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 CHIESI FARMACEUTICI S.P.A
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 DENDREON PHARMACEUTICALS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 ENZYVANT THERAPEUTICS GMBH
13.12.1 COMPANY SNAPSHOT
13.12.2 RODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 FERRING B.V.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENT
13.14 JANSSEN PHARMACEUTICALS, INC.
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 MALLINCKRODT.
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENT
13.16 ORCHARD THERAPEUTICS PLC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.
13.17.1 COMPANY SNAPSHOT
13.17.2 PRODUCT PORTFOLIO
13.17.3 RECENT DEVELOPMENT
13.18 SIBONO
13.18.1 COMPANY SNAPSHOT
13.18.2 PRODUCT PORTFOLIO
13.18.3 RECENT DEVELOPMENT
13.19 SPARK THERAPEUTICS, INC.
13.19.1 COMPANY SNAPSHOT
13.19.2 PRODUCT PORTFOLIO
13.19.3 RECENT DEVELOPMENT
13.2 UNIQURE NV.
13.20.1 COMPANY SNAPSHOT
13.20.2 REVENUE ANALYSIS
13.20.3 PRODUCT PORTFOLIO
13.20.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 29 U.S. VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 30 U.S. NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 31 U.S. GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 32 U.S. GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 U.S. GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 35 CANADA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 36 CANADA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 37 CANADA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 38 CANADA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 CANADA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 41 MEXICO VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 42 MEXICO NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 43 MEXICO GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 44 MEXICO GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 45 MEXICO GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA GENE THERAPY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA GENE THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA GENE THERAPY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA GENE THERAPY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA GENE THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA GENE THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA GENE THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA GENE THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA GENE THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA GENE THERAPY MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISORDERS AND GROWING DEMAND FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA GENE THERAPY MARKET FROM 2023 TO 2030
FIGURE 12 THE VIRAL VECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GENE THERAPY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA GENE THERAPY MARKET
FIGURE 14 NORTH AMERICA GENE THERAPY MARKET: BY VECTOR TYPE, 2022
FIGURE 15 NORTH AMERICA GENE THERAPY MARKET: BY VECTOR TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA GENE THERAPY MARKET: BY VECTOR TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA GENE THERAPY MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA GENE THERAPY MARKET: BY METHOD, 2022
FIGURE 19 NORTH AMERICA GENE THERAPY MARKET: BY METHOD, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA GENE THERAPY MARKET: BY METHOD, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA GENE THERAPY MARKET: BY METHOD, LIFELINE CURVE
FIGURE 22 NORTH AMERICA GENE THERAPY MARKET: BY APPLICATION, 2022
FIGURE 23 NORTH AMERICA GENE THERAPY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA GENE THERAPY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA GENE THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA GENE THERAPY MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA GENE THERAPY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA GENE THERAPY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA GENE THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA GENE THERAPY MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA GENE THERAPY MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA GENE THERAPY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA GENE THERAPY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA GENE THERAPY MARKET: VECTOR TYPE (2023-2030)
FIGURE 35 NORTH AMERICA GENE THERAPY MARKET: COMPANY SHARE 2022 (%)
